Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 22450873)

1.

Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors.

Aregbe AO, Sherer EA, Egorin MJ, Scher HI, Solit DB, Ramanathan RK, Ramalingam S, Belani CP, Ivy PS, Bies RR.

Cancer Chemother Pharmacol. 2012 Jul;70(1):201-5. doi: 10.1007/s00280-012-1859-1. Epub 2012 Mar 27.

2.

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.

Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, Chen M, Steinberg SM, Muir CA, Yancey MA, Horneffer YR, Juwara L, Melillo G, Ivy SP, Merino M, Neckers L, Steeg PS, Conley BA, Giaccone G, Doroshow JH, Murgo AJ.

Eur J Cancer. 2010 Jan;46(2):340-7. doi: 10.1016/j.ejca.2009.10.026. Epub 2009 Nov 27.

3.

Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.

Glaze ER, Lambert AL, Smith AC, Page JG, Johnson WD, McCormick DL, Brown AP, Levine BS, Covey JM, Egorin MJ, Eiseman JL, Holleran JL, Sausville EA, Tomaszewski JE.

Cancer Chemother Pharmacol. 2005 Dec;56(6):637-47. Epub 2005 Jun 29.

PMID:
15986212
4.

Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.

Kontny NE, Würthwein G, Joachim B, Boddy AV, Krischke M, Fuhr U, Thompson PA, Jörger M, Schellens JH, Hempel G.

Cancer Chemother Pharmacol. 2013 Mar;71(3):749-63. doi: 10.1007/s00280-013-2069-1. Epub 2013 Jan 13.

PMID:
23314734
5.

A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.

Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, Workman P, Judson I.

Clin Cancer Res. 2011 Mar 15;17(6):1561-70. doi: 10.1158/1078-0432.CCR-10-1927. Epub 2011 Jan 28.

6.

A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin.

Furth AF, Mandrekar SJ, Tan AD, Rau A, Felten SJ, Ames MM, Adjei AA, Erlichman C, Reid JM.

Cancer Chemother Pharmacol. 2008 Jan;61(1):39-45. Epub 2007 Mar 20.

PMID:
17909811
7.

Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.

Wilhelm AJ, de Graaf P, Veldkamp AI, Janssen JJ, Huijgens PC, Swart EL.

Br J Clin Pharmacol. 2012 Apr;73(4):553-63. doi: 10.1111/j.1365-2125.2011.04116.x.

8.

Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.

Bonate PL, Floret S, Bentzen C.

Br J Clin Pharmacol. 2004 Aug;58(2):142-55.

9.

Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.

Musuamba FT, Rousseau A, Bosmans JL, Senessael JJ, Cumps J, Marquet P, Wallemacq P, Verbeeck RK.

Clin Pharmacokinet. 2009;48(11):745-58. doi: 10.2165/11318060-000000000-00000.

PMID:
19817503
10.
11.

Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.

Conil JM, Georges B, Ruiz S, Rival T, Seguin T, Cougot P, Fourcade O, Pharmd GH, Saivin S.

Br J Clin Pharmacol. 2011 Jan;71(1):61-71. doi: 10.1111/j.1365-2125.2010.03793.x.

12.

Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.

Narwal R, Roskos LK, Robbie GJ.

Clin Pharmacokinet. 2013 Nov;52(11):1017-27. doi: 10.1007/s40262-013-0085-2.

13.

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.

Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G, Larson S, Schwartz L, Egorin MJ, Rosen N, Scher HI.

Clin Cancer Res. 2007 Mar 15;13(6):1775-82.

14.

Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.

Chen X, Bies RR, Ramanathan RK, Zuhowski EG, Trump DL, Egorin MJ.

Cancer Chemother Pharmacol. 2005 Mar;55(3):237-43. Epub 2004 Oct 19.

PMID:
15503027
15.

Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors.

Ramanathan RK, Egorin MJ, Erlichman C, Remick SC, Ramalingam SS, Naret C, Holleran JL, TenEyck CJ, Ivy SP, Belani CP.

J Clin Oncol. 2010 Mar 20;28(9):1520-6. doi: 10.1200/JCO.2009.25.0415. Epub 2010 Feb 22.

16.

Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.

Monchaud C, de Winter BC, Knoop C, Estenne M, Reynaud-Gaubert M, Pison C, Stern M, Kessler R, Guillemain R, Marquet P, Rousseau A.

Clin Pharmacokinet. 2012 Mar 1;51(3):175-86. doi: 10.2165/11594760-000000000-00000.

PMID:
22339449
17.

A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study.

Weigel BJ, Blaney SM, Reid JM, Safgren SL, Bagatell R, Kersey J, Neglia JP, Ivy SP, Ingle AM, Whitesell L, Gilbertson RJ, Krailo M, Ames M, Adamson PC.

Clin Cancer Res. 2007 Mar 15;13(6):1789-93.

18.

A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.

Ramalingam SS, Egorin MJ, Ramanathan RK, Remick SC, Sikorski RP, Lagattuta TF, Chatta GS, Friedland DM, Stoller RG, Potter DM, Ivy SP, Belani CP.

Clin Cancer Res. 2008 Jun 1;14(11):3456-61. doi: 10.1158/1078-0432.CCR-07-5088.

20.

Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.

Perez-Ruixo JJ, Zannikos P, Hirankarn S, Stuyckens K, Ludwig EA, Soto-Matos A, Lopez-Lazaro L, Owen JS.

Clin Pharmacokinet. 2007;46(10):867-84.

PMID:
17854236
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk